Back
Bicara Therapeutics Stock Price Chart
Why Private Investors Didn't Lose a Penny in the Market's Recent $1T Crash
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Buy
62
BCAX
Bicara Therapeutics
Last Price:
$13.41
Seasonality Move:
--
7 Day Trial
ALL ACCESS PASS
$
7
Apple's Drop in iPhone Sales Opens the Door for New Entrant
This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.-
The current trend is relatively stagnant and BCAX is experiencing slight buying pressure.
Bicara Therapeutics Price Chart Indicators
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 13.06 | Buy |
| 20-day SMA: | 13.52 | Sell |
| 50-day SMA: | 12.95 | Buy |
| 200-day SMA: | 0 | Buy |
| 8-day EMA: | 13.25 | Buy |
| 20-day EMA: | 13.32 | Buy |
| 50-day EMA: | 13.78 | Sell |
| 200-day EMA: | 11.3 | Buy |
Bicara Therapeutics Technical Analysis Indicators
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.08 | Sell |
| Relative Strength Index (14 RSI): | 49.87 | Sell |
| Chaikin Money Flow: | 54188 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (12.38 - 14.44) | Sell |
| Bollinger Bands (100): | (12.37 - 20.31) | Sell |
Bicara Therapeutics Technical Analysis
| Mar 14 | Mar 17 | Mar 18 | Mar 19 | Mar 20 | Mar 21 | Mar 24 | Mar 25 | Mar 26 | Mar 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar | ||||||||||
| 14 | 17 | 18 | 19 | 20 | 21 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Technical Analysis for Bicara Therapeutics Stock
Is Bicara Therapeutics Stock a Buy?
-
Bicara Therapeutics share price is 13.40 while BCAX 8-day simple moving average is 13.06, which is a Buy signal.
-
The stock price of BCAX is 13.40 while Bicara Therapeutics 20-day SMA is 13.52, which makes it a Sell.
-
Bicara Therapeutics 50-day simple moving average is 12.95 while BCAX share price is 13.40, making it a Buy technically.
-
BCAX stock price is 13.40 and Bicara Therapeutics 200-day simple moving average is 0.00, creating a Buy signal.
BCAX Technical Analysis vs Fundamental Analysis
Buy
62
Bicara Therapeutics (BCAX)
is a Buy
Is Bicara Therapeutics a Buy or a Sell?
-
Bicara Therapeutics stock is rated a BuyThe current Bicara Therapeutics [BCAX] share price is $13.40. The Score for BCAX is 62, which is 24% above its historic median score of 50, and infers lower risk than normal.
Bicara Therapeutics Stock Info
Market Cap:
617.2M
Price in USD:
13.40
Share Volume:
333.7K
Bicara Therapeutics 52-Week Range
52-Week High:
28.09
52-Week Low:
11.10
Buy
62
Bicara Therapeutics (BCAX)
is a Buy
Bicara Therapeutics Share Price Forecast
-
What is the Bicara Therapeutics stock price today?The Bicara Therapeutics stock price is 13.40 USD today.
-
Will BCAX stock go up or go down?Bicara Therapeutics> share price is forecast to RISE/FALL based on technical indicators
-
Is Bicara Therapeutics overvalued?According to simple moving average, exponential moving average, oscillators, and other technical indicators, Bicara Therapeutics is not overvalued.
Is Bicara Therapeutics Stock a Buy?
-
Bicara Therapeutics share price is 13.40 while BCAX 8-day exponential moving average is 13.25, which is a Buy signal.
-
The stock price of BCAX is 13.40 while Bicara Therapeutics 20-day EMA is 13.32, which makes it a Buy.
-
Bicara Therapeutics 50-day exponential moving average is 13.78 while BCAX share price is 13.40, making it a Sell technically.
-
BCAX stock price is 13.40 and Bicara Therapeutics 200-day simple moving average is 11.30, creating a Buy signal.
Fundamental Analysis of Bicara Therapeutics
Is Bicara Therapeutics a good investment?
-
Analysts estimate an earnings increase this quarter of $0.11 per share, a decrease next quarter of $0.00 per share, an increase this year of $1.07 per share, and a decrease next year of $0.47 per share.
Technical Analysis of Bicara Therapeutics
Should I short Bicara Therapeutics stock?
-
BCAX Moving Average Covergence Divergence (MACD) indicator is -0.08, suggesting Bicara Therapeutics is a Sell
-
Bicara Therapeutics Relative Strength Index (RSI) is 49.87, which suggest Bicara Therapeutics is oversold
-
The Bollinger Bands (25) for Bicara Therapeutics is (12.38 - 14.44), which suggest Bicara Therapeutics is a Sell
-
The Bollinger Bands (100) for Bicara Therapeutics is (12.37 - 20.31), which suggest Bicara Therapeutics is a Sell
* Bicara Therapeutics stock forecasts short-term for next days and weeks may differ from long term prediction for next month and year based on timeline differences.